Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 9:30 a.m. Eastern Time in New York, NY.
A live audio webcast of the presentation will be available by visiting the “Investors” section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for at least 30 days following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has four programs in the clinic targeting important oncology/immuno-oncology pathways: (1) AB928, a dual adenosine receptor antagonist (A2a and A2b receptors), being evaluated in several Phase 1/1b trials in combination with multiple regimens across a range of tumor types, (2) AB680, a small molecule inhibitor of CD73 progressing into a Phase 1/1b pancreatic cancer trial, (3) AB122, an anti-PD-1 antibody progressing into a biomarker-selected tumor-agnostic Phase 1b trial, and (4) AB154, an anti-TIGIT antibody being evaluated in combination with AB122. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has created a world-class drug discovery organization focused on the development of a growing portfolio of innovative therapies for the treatment of cancer. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005858/en/
Source: Arcus Biosciences
View this news release online at:
http://www.businesswire.com/news/home/20190919005858/en
